Remove Aortic Remove Heart Failure Remove Tricuspid
article thumbnail

FDA Advisory Committee Votes in Favor of Abbott’s First-of-its-kind Triclip System to Treat People with a Leaky Tricuspid Heart Valve

DAIC

Food and Drug Administration ( FDA ) confirmed 13 to 1, with 0 abstention that the benefits of Abbott's TriClip™ transcatheter edge-to-edge repair (TEER) system outweighed the risks for the treatment of people with tricuspid regurgitation (TR). On the final question of the benefit of TriClip versus the risk, the vote was 13 to 1 in favor.

Tricuspid 102
article thumbnail

Abbott Announces FDA Approval of First-of-its-kind Device to Repair Leaky Tricuspid Heart Valve, TriClip

DAIC

Food and Drug Administration (FDA) approval of its TriClip, a first-of-its-kind device to repair leaky tricuspid heart valve, for which more than 1.6 are affected by tricuspid regurgitation, 1 which can severely impact quality of life. Abbott has announced U.S million people in the U.S. are estimated to be affected. and Lynn C.

Tricuspid 105
article thumbnail

Eagle’s Eye View: Sacubitril/Valsartan in Decompensated Heart Failure; Discordant Aortic Stenosis and Transcatheter Treatment of Tricuspid Valve Regurgitation

American College of Cardiology

In this week’s View, Dr. Eagle looks at sacubitril/valsartan in patients hospitalized with decompensated heart failure, then examines the prevalence and outcomes of patients with discordant high gradient aortic stenosis.

article thumbnail

Clinical management and therapeutic optimization of patients with heart failure with reduced ejection fraction and low blood pressure. A clinical consensus statement of the Heart Failure Association (HFA) of the ESC

European Journal of Heart Failure

Proposed approach for clinical management and therapeutic optimization in patients with heart failure with reduced ejection fraction and low blood pressure. Low blood pressure with major or mild symptoms. **SBP SBP <80mmHg or symptomatic low BP or asymptomatic low BP.

article thumbnail

Edwards Lifesciences to Sell Critical Care to BD

DAIC

The sale enhances Edwards’ balance sheet flexibility for disciplined investments in technologies for aortic, mitral, tricuspid and pulmonic patients, as well as new therapeutic areas for interventional heart failure. Edwards will use the after-tax cash proceeds to fund strategic growth investments.

article thumbnail

AISAP’s CARDIO AI-powered Diagnostic Assessment Software Receives FDA Clearance

DAIC

We know that structural heart disease and heart failure are the leading causes of hospitalization and morbidity in the U.S. Standalone performance for significant major valve disease pathology (aortic stenosis and regurgitation and mitral and tricuspid regurgitation) had a 93 percent sensitivity and 93 percent specificity.

article thumbnail

Tricuspid regurgitation: Frequency, clinical presentation, management and outcome among patients with severe left?sided valvular heart disease in Europe. Insights from the ESC?EORP Valvular Heart Disease II survey

European Journal of Heart Failure

Tricuspid regurgitation (TR): frequency, clinical presentation, management and outcome among patients with severe left-sided valvular heart disease in Europe. ESC-EORP, European Society of Cardiology-EURObservational Research Programme; TV, tricuspid valve.